Note: Descriptions are shown in the official language in which they were submitted.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
1.
ORAL MILLED VACCINES AND METHOD FOR PROVIDING SAME
FIELD toF THE INVENTION
The present invention relates to a method for selecting unicellular microbial
isolate(s) for
use in oral killed vaccines, for inducing a protective mucosal immune response
against
abnormal colonisation of a mucosal surface by the microbe. Oral killed
vaccines for the
prophylaxis or treatment of such infections are also provided.
BACKGROUND OF' THE INVENTION
Anti-bacterial vaccines are known in the art and examples include Haemophilus
influenzae B vaccine which consists of bacterial polysaccharide conjugated
with tetanus
toxoid protein. Killed bacterial vaccines for the prophylaxis or treatment of
enteric
infections have also been known for some time and a killed bacterial vaccine
for typhoid
fever is commercially available. These vaccines are predominantly if not
exclusively
administered by injection and serve as "classic" vaccines in that they aim to
stimulate a
systemic antibody response to provide protection against disease.
Antigen administered orally is processed by gut-associated lymphoid tissue
(GALT)
differently from systemic lymphoid tissue. Teleologically, this can be
understood in
terms of mucosal physiologically where environmental "antigen" needs to be
excluded
but not at the cost of damaging mucosal "inflammation". A powerful suppression
mechanism therefore exists, to minimise potentially damaging immune responses
to such
antigen. This concept was originally identified as "split tolerance" where a
systemic
immune response (ie. mediated by the generation of antibody) was associated
with the
failure to detect a mucosal antibody response (tolerance). Research using
orally
administered killed influenza virus shows that an antibody response is
stimulated over a
narrow range of antigen dose. This immunisation "zone" is flanked by low and
high
"zone" tolerance. The same concept applies to cellular immunity though the
zone in
which T-lymphocyte-mediated responses may be stimulated appears to be
marginally
wider with protection occurring without an antibody response. The outcome of
antigen
interaction with GALT is the selective migration of B and T-lymphocytes to
distant
mucosal sites of infection where they mediate protection.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
2.
An oral killed bacterial vaccine against infection by non-typable Haemoplzilus
imluenzae
(NTHi) is also known in the art. NTHi is the bacteria most commonly linked
with nasal
and bronchus colonisation in subjects with chronic lung disease, and has been
linked to
acute episodes of bronchitis in these subjects. A significant factor in the
generation of
acute bronchitis in such subjects is the uncontrolled and inappropriate
migration of
neutrophils into the bronchus lumen in response to the colonising bacteria.
The
accumulation of neutrophil-laden fluid within the bronchi results in purulent
sputum. The
use of the oral NTHi killed bacterial vaccine has been shown to protect
against purulent
sputum production, high levels of bacterial colonisation of the airways and
environmental
spread of the bacteria as assessed by acquisition of infection by bystander
subjects. The
NTHi vaccine stimulates the common mucosal system following activation of GALT
and
more specifically, Peyer's patches in the intestines.
Oral non-adjuvenated monobacterial vaccines comprising killed bacteria for
providing
mucosal immunity particularly in patients with long term chronic lung disease
are
described in international patent application No. PCT/AU86/00071.
Specifically, the
application indicates that the immunisation efficacy of the vaccine arises
from the
absence of adjuvant, which would normally be included in such vaccine
formulations to
promote an immune response. The generation of the immune response in the
absence of
the adjuvant was reasoned to be due to the response elicited by the killed
bacteria being
insufficient to trigger dominant suppressor T-cell populations in the lungs of
the patients
evaluated.
SUMMARY OF THE INVENTION
Broadly stated, the present invention relates to the provision of oral killed
vaccines for
protecting against abnormal microbial colonisation and stems from the
recognition that
there is a marked variation in the clearance of such infections elicited by
oral killed
vaccines in an outbred population, reflecting the genetic variation in the
population. The
variation in mucosal immunity associated with the use of prior art oral killed
bacterial
vaccines is believed to arise from the use of less optimal or randomly chosen
microbial
isolates in the vaccines, due to the failure to recognise the significant
variability in the
capacity of different isolates of a microbe to activate antigen-presenting
cells and T-
lymphocytes. Given the observed variability, the selection of the isolate(s)
is critical for
optimising the degree of activation of the common mucosal system in different
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
3.
individuals in an outbred population. Methodology provided in one or more
embodiments of the present invention enables the selection of isolate(s) for
optimising
oral killed vaccines.
More particularly, in one aspect of the present invention there is provided a
method for
selecting a microbial isolate for an oral killed vaccine against abnormal
microbial
colonisation of a mucosal surface, the method comprising:
evaluating capacity of a plurality of different isolates of a unicellular
microbe to
activate antigen responsive cells to provide activation data for each
microbial isolate;
evaluating effectiveness of the isolates in reducing infection of a mucosal
surface
by the microbe to provide clearance data for each microbial isolate; and
selecting an isolate from the microbial isolates, the activation data and
clearance
data for which correlate and is optimal for generating mucosal immunity
against the
microbe compared to the, or each, other of the isolates, or an isolate the
activation data
for which is optimal and a further isolate the clearance data for which is
optimal,
compared to the, or each, other of the isolates, respectively, for use in
formulating the
vaccine.
In another aspect of the present invention there is a method for providing an
oral killed
vaccine against abnormal microbial colonisation of a mucosal surface, the
method
comprising:
evaluating capacity of a plurality of different isolates of a unicellular
microbe to
activate antigen responsive cells to provide activation data for each
microbial isolate;
evaluating effectiveness of the isolates in reducing infection of a mucosal
surface
by the microbe to provide clearance data for each microbial isolate;
selecting an isolate from the plurality of isolates, the activation data and
clearance
data for which correlate and is optimal for generating mucosal immunity
against the
microbe compared to the, or each, other of the isolates, or an isolate the
activation data
for which is optimal and a further isolate the clearance data for which is
optimal,
compared to the, or each, other of the microbial isolates, respectively, for
use in
formulating the vaccine; and
formulating the vaccine using the selected isolate or isolates.
Typically, an isolate for which both the activation data and the clearance
data is optimal
compared to the other of the isolates will be selected.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
4.
Preferably, the mucosal immunity will comprise predominantly a cellular immune
response.
Preferably, the isolates utilised for providing the activation and clearance
data will be
killed isolates of the microbe. However, the invention is not limited thereto
and the
activation and clearance data may be obtained from live isolates and the
selected
isolate(s) subsequently killed for use in the vaccine.
The antigen responsive cells activated by the isolate(s) will normally
comprise one or
both of antigen presenting cells and T-lymphocytes and preferably, will
comprise both
types of cells. The antigen presenting cells will typically comprise
macrophages. Most
preferably, the T-lymphocytes will be Thl cells. The activation of the antigen
responsive
cells is to be taken in its broadest sense to encompass direct and/or indirect
activation by
the isolate(s). By "direct" activation is meant the isolate(s) activate at
least some of the
antigen responsive cells by contact with the cells such as when a microbial
isolate is
bound or phagocytosed by them. By "indirect" activation is meant at least some
of the
antigen responsive cells are activated by interaction with the cells such as
macrophages
that have contacted the isolate or for instance, by cytokine(s) or other
chemical
messenger(s) the release of which has been elicited or induced by the
isolate(s), or by
substances such as toxins or antigens secreted by the isolate(s), or a
combination of the
foregoing possibilities.
The level of activation of the antigen responsive cells can be evaluated by
measuring one
or more parameters associated with activation of the cells. Preferably, the
capacity of the
isolate(s) to activate both antigen presenting cells and T-lymphocytes will be
evaluated.
In particularly preferred embodiments, the activation of the antigen
responsive cells
achieved by each isolate will be evaluated by measuring at least one parameter
indicative
of the level of activation of the antigen presenting cells and at least one
other parameter
indicative of the level of activation of the T-Iymphocytes. Most preferably,
isolate(s) the
activation data for which is optimal for activating both antigen presenting
cells and T-
lymphocytes compared to the other isolate(s) tested will be selected for use
in the
preparation of the oral killed vaccine.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
5.
Preferably, an isolate the activation data for which is indicative of the
capacity of the
isolate to elicit a cytokine response characterised by an IL-10: IL-12 ratio
of about 30 or
less will be selected for use in formulating the oral killed vaccine.
Hence, in another aspect of the present invention there is provided a method
for selecting
a microbial isolate for an oral killed vaccine against abnormal microbial
colonisation of a
mucosal surface, the method comprising:
evaluating capacity of a plurality of different isolates of a unicellular
microbe to
induce expression of IL-10 and IL-12 in antigen responsive cells; and
selecting at least one isolate from the microbial isolates, that induces
optimal
expression of IL-12 relative to IL-10 compared to the, or each, other of the
isolates,
respectively, for use in formulating the vaccine.
In still another aspect of the present invention there is provided a method
for providing an
oral killed vaccine against abnormal microbial colonisation of a mucosal
surface, the
method comprising:
evaluating capacity of a plurality of different isolates of a unicellular
microbe to
induce expression of IL-10 and IL-12 in antigen responsive cells;
selecting at least one isolate from the microbial isolates, that induces
optimal
expression of IL-12 relative to IL-10 compared to the, or each, other of the
isolates,
respectively, for use in formulating the vaccine; and
formulating the vaccine using the isolate.
The unicellular microbe can be any such microbe having the capacity to
colonise a
mucosal surface of a mammal and may for instance be selected from the group
consisting
of bacteria, fungi and yeast. Typically, the microbe will be a bacteria and
the vaccine will
therefore be an oral killed bacterial vaccine. Preferably, the selected
isolate(s) will be
used in the vaccines of the invention as whole killed organisms. However, the
invention
is not limited to the use of whole killed organisms and vaccines may be
provided
comprising particulate matter derived from the outer cellular membrane of the
selected
isolate(s).
In yet another aspect, the present invention relates to an oral killed vaccine
provided by a
method of the invention.
CA 02577165 2008-04-23
6
A vaccine of the invention may be directed against infection of any mucosal
site
including chronic and acute such infections. The infection can be the result
of transient
exposure to a microbial pathogen which does not normally colonise the mucosal
site or
for instance, an opportunistic infection arising from microbial flora normally
found at the
site.
Accordingly, in another aspect, there is provided a method for the prophylaxis
or
treatment of an infection of a mucosal surface in a mammal by a unicellular
microbe, the
method comprising:
administering to the mammal an effective amount of an oral killed vaccine of
the
invention for generating mucosal immunity against the microbe.
The mammal may be any mammal treatable with an oral killed bacterial vaccine
of the
invention. For instance, the mammal may be a primate, a member of the rodent
family
such as a rat or mouse, or a member of the bovine, porcine, ovine or equine
families.
Preferable, however, the mammal will be a human being.
Throughout this specification the word "comprise", or variations such as
"comprises" or
"comprising", will be understood to imply the inclusion of a stated element,
integer or
step, or group of elements, integers or steps, but not the exclusion of any
other element,
integer or step, or group of elements, integers or steps.
Any discussion of documents, acts, materials, devices, articles or the like
which has been
included in the present specification is solely for the purpose of providing a
context for the
present invention. It is not to be taken as an admission that any or all of
these matters
form part of the prior art base or were common general knowledge in the field
relevant to
the present invention as it existed in Australia or elsewhere before the
priority date of each
claim of this application.
The features and advantages of the present invention will become further
apparent from
the following description of preferred embodiments.
In accordance with one aspect of the present invention, there is provided a
use of at least
one isolate of a unicellular microbe in the manufacture of an oral killed
vaccine against
microbial colonization of a mucosal surface, wherein the isolate is selected
from a group
of isolates of the microbe on the basis of capacity of the isolate to
optimally activate
antigen responsive cells and to clear infection of a mucosal surface by the
microbe
compared to the other isolates in the group, or wherein an isolate is selected
from the
group of isolates on the basis of capacity of that isolate to optimally
activate the antigen
CA 02577165 2012-10-25
6a
responsive cells and a further isolate is selected from the group on the basis
of its
capacity to optimally clear infection of the mucosal surface by the microbe,
compared to
the other isolates in the group respectively.
In accordance with another aspect of the present invention, there is provided
a use of at
least one isolate of a unicellular microbe as an oral killed vaccine against
microbial
colonization of a mucosal surface, wherein the isolate is selected from a
group of
isolates of the microbe on the basis of capacity of the isolate to optimally
activate
antigen responsive cells and to clear infection of a mucosal surface by the
microbe
compared to the other isolates in the group, or wherein an isolate is selected
from the
group of isolates on the basis of capacity of that isolate to optimally
activate the antigen
responsive cells and a further isolate is selected from the group on the basis
of its
capacity to optimally clear infection of the mucosal surface by the microbe,
compared to
the other isolates in the group respectively.
In accordance with a further aspect of the present invention, there is
provided a use of at
least one isolate of a unicellular microbe in the manufacture of an oral
killed vaccine
against microbial colonisation of a mucosal surface, wherein the isolate is
selected from
a group of isolates of the microbe on the basis of capacity of the isolate to
optimally
induce expression of IL-2 relative to IL-10 in antigen responsive cells
compared to the
other isolates in the group.
In accordance with a further aspect of the present invention, there is
provided a use of at
least one isolate of a unicellular microbe as an oral killed vaccine against
microbial
colonisation of a mucosal surface, wherein the isolate is selected from a
group of
isolates of the microbe on the basis of capacity of the isolate to optimally
induce
expression of IL-2 relative to IL-10 in antigen responsive cells compared to
the other
isolates in the group.
According to another aspect, there is provided a use of at least one isolate
of a
unicellular microbe in the manufacture of an oral killed vaccine against
microbial
colonization of a mucosal surface, wherein the isolate is selected from a
group of
isolates of the microbe on the basis of capacity of the isolate to induce IL-
12 expression
by antigen responsive cells, to activate T-lymphocytes, and to clear infection
of a
mucosal surface by the microbe compared to the other isolates in the group, or
wherein
an isolate is selected from the group of isolates on the basis of capacity of
that isolate to
induce IL-12 expression by the antigen responsive cells and to activate T-
lymphocytes
and a further isolate is selected from the group on the basis of its capacity
to optimally
CA 02577165 2013-06-12
6b
clear infection of the mucosal surface by the microbe, compared to the other
isolates in
the group respectively.
According to a further aspect, there is provided a use of at least one isolate
of a
unicellular microbe as an oral killed vaccine against microbial colonization
of a
mucosal surface, wherein the isolate is selected from a group of isolates of
the
microbe on the basis of capacity of the isolate to induce IL-12 expression by
antigen responsive cells, to activate T-lymphocytes, and to clear infection of
a
mucosal surface by the microbe compared to the other isolates in the group, or
wherein an isolate is selected from the group of isolates on the basis of
capacity
of that isolate to induce IL-12 expression by the antigen responsive cells and
to
activate T-lymphocytes and a further isolate is selected from the group on the
basis of its capacity to optimally clear infection of the mucosal surface by
the
microbe, compared to the other isolates in the group respectively.
According to another aspect, there is provided a method for selecting a
microbial
isolate for use as an oral killed vaccine against abnormal microbial
colonisation of
a mucosal surface, the method comprising:
treating antigen responsive cells with a plurality of different isolates of a
unicellular microbe and evaluating the capacity of the plurality of different
isolates
to induce expression of IL-10 and IL-12 in the antigen responsive cells; and
selecting an isolate from the microbial isolates, that induces an IL-10:IL-12
ratio of 15 or less, for use in formulating the vaccine.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a graph showing reduction of NTHi colonisation in the respiratory
tract of
BALB/c mice by different whole cell killed isolates of the bacteria
administered orally.
Figure 2 is a graph showing reduction of S. aureus colonisation in the nose of
BALB/c
mice by different whole cell killed isolates of the bacteria administered
orally.
CA 02577165 2012-10-25
7
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Vaccines embodied by the invention find particular application in the
prophylaxis or
treatment of lung and upper respiratory tract infections. However, the
invention is not
limited thereto and mucosal immunity resulting from activation of the common
mucosal
system may provide protection or treatment against infections at other mucosal
sites of
the body including infections of the oral, nasal, oropharyngeal, nasal
pharyngeal,
pharyngeal, digestive, vaginal, eye associated, and urinary mucosal surfaces.
The vaccine
may contain bacteria selected for instance from Chlamydia species, Haemophilus
species,
Non-typable Haemophilus species, Pseudomonas species, Streptococcus species,
Staphylococcus species, E. coli species, MYcoplasma species and Helicobacter
species
amongst others, or incorporate combinations of different species of bacteria
or of other
unicellular microbes. Microbes other than bacteria that may be used in oral
killed
vaccines according to the invention include Candida species such as Candida
albicans
and yeast species ,such as Saccharomyces species. Particularly preferred oral
killed
bacterial vaccines embodied by the invention are vaccines for the prophylaxis
or
treatment of mucosal infections by bacteria selected from the group consisting
of Non-
typable H. influenzae (NTHi), S. aureus, Ps. aeruginosa, S. pneumoniae and
combinations thereof.
While the primary application of a vaccine embodied by the invention is to
generate
mucosal immunity against the particular bacterial infection(s) for which the
vaccine is
provided, which may occur at various mucosal sites, the vaccine can also be
used for the
treatment or prophylaxis of diseases or conditions exacerbated by the
infection(s).
P. aeruginosa for instance can colonise not only the respiratory tract but can
also infect
eye mucosa and the ear cavity. Non-typable H. influenzae (NTHi) has also been
implicated in a range of infectious conditions including otitis media and in
the
exacerbation of pneumonia and chronic bronchitis. Accordingly, a vaccine
containing
one or more killed NTHi isolates of this bacteria may be administered for the
prophylaxis
or treatment of those conditions. Similarly, vaccines of the invention
comprising killed
H. influenzae, S. pneumoniae or P. aeruginosa may be utilised in the
prophylaxis or
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
8.
treatment of bronchitis or pneumonia, and acute infections in cystic fibrosis
and chronic
obstructive airways disease, sinus disease, compromised lung function and
other lung and
respiratory tract diseases and disorders. These vaccines also find particular
application in
the prophylaxis or treatment of superinfection by the corresponding bacteria
following
infection by influenzae virus or other virus, particularly in the elderly.
While it is preferable to use whole killed isolate(s) in vaccines of the
invention,
particulate cell surface matter comprising surface antigens of the isolate(s)
may be
utilised as well, or instead, of whole killed organisms. In a particularly
preferred
embodiment, the outer cellular membrane fraction of the organisms will be
utilised. The
particulate matter can be prepared by disrupting killed or viable selected
isolate(s) by
sonication or other suitable technique and if desired, separating the required
fraction from
other cellular components such as by centrifugation, filtration and/or other
appropriate
technique known in the art. Any suitable method which achieves the required
level of
cellular disruption may be employed including sonication or dissolution
utilising
appropriate surfactants and agitation. When sonication is employed, the
isolate may be
subjected to a number of sonication steps in order to obtain the desired
degree of cellular
disruption or generation of particulate matter of a desired size. The fraction
of particulate
matter utilised may be selected by comparing the response of antigen
responsive cells to
different fractions of the isolate(s) and selecting the fraction which
maximises the
immune response by the cells.
To evaluate the capacity of a microbial isolate or particulate matter thereof
to activate the
antigen responsive cells, any parameter which is indicative of the level of
activation of
the cells may be evaluated. Particularly, preferred parameters include one or
more of
cellular proliferation, cell surface antigen expression, measurement of cell
effector
functions, and cytokine production.
Cellular proliferation and in particular, T-cell proliferation, may be
conveniently
evaluated by cell counts, 3H-thymidine uptake and/or MTT assays.
Cytokine expression may be measured directly by capture or sandwich enzyme
linked
immunosorbent assays (ELISA), or indirectly by cell growth assays in which the
cytokine
of interest acts as a growth factor or inhibitor. Similarly, cytokine
expression may be
evaluated by determining the level of expression of mRNA coding for the
cytokine by
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
9,
employing reverse transcriptase polymerase chain reaction (RT-PCR) or by in-
situ
hybridisation protocols utilising single cells and specific oligonucleotides
probes as is
known in the art.
The protective immune response generated by the vaccine will typically be
predominantly
mediated by Thl T-lymphocytes which differentiate from proliferating CD4+ T-
lymphocytes in the presence of IL-12 and IFN- 7. IL-12 is produced by antigen
presenting cells in the early stages of activation. Thl T-lymphocytes
stimulate infected
macrophages through secretion of IFN- 7 and interaction of the CD40 ligand
expressed by
Thl cells with the CD40 receptor expressed by macrophages. More broadly, Thl
cells
stimulate the antibacterial mechanisms of phagocytic cells (eg. neutrophils
and
macrophages) and release cytokines that attract such phagocytic cells to sites
of infection.
Besides IFN- 7, Thl cells typically also secrete IL-12 and TNF-13.
While both Thl and Th2 cells secrete IL-3, GM-CSF and for instance TNF-a, the
overall
cytokine profiles for Thl and Th2 cells are different. More particularly,
activation of Th2
cells results predominantly in a humoral immune response characterised by the
activation
of B-lymphocytes and the generation of antibodies by the activated B cells,
while Thl
cells mediate a predominantly non-antibody cellular immune response. Cytokines
characteristic of Th2 cell driven immune response include IL-4, IL-5, IL-10,
IL-13 and
TGF-P. Hence, detection of the secretion of one or more of IL-12, IFN- y, or
other
cytokines characteristic of activated antigen-presenting cells and Thl
committed CD4+ T-
lymphocytes, is useful in evaluating the capacity of a given microbial isolate
to activate
the common mucosal system. Preferably, the level of IL-12 secretion will be
measured to
provide an indication of the degree of activation of antigen presenting cells
by the
microbial isolate(s) being evaluated. Similarly, the level of IFN- 7 secretion
will typically
be measured to provide an indication of the level of T-lymphocytes activation
achieved
by the microbial isolate(s).
In particularly preferred embodiments, the activation data may comprise a
ratio indicating
expression IL-10 relative to IL-12. IL-10 inhibits the release of cytokines
such as IL-12
by macrophages and so inhibits Thl cell activation. The ratio is therefore
indicative of
the level of a Thl lymphocyte response elicited by a microbial isolate. Thus,
an isolate
selected for activating the antigen responsive cells will desirably elicit a
cytokine
response characterised by a low IL-10:IL-12 ratio but high expression of IFN-
7.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
10.
Preferably, the ratio will be less than 30, more preferably less than 20, 15,
10, 5 and even
4.
The vaccine will typically comprise the selected bacterial isolate(s) in an
amount of
between about 5% to about 80% w/w of the vaccine composition. As will be
appreciated,
the number of each isolate in the vaccine will be such that an effective
dosage will be
delivered to the mammal for activation of the common mucosal system taking
into
account the proposed mode of delivery and nature of the vaccine (eg. powder,
liquid,
aerosol delivery etc). The dosage of the, or each, bacterial isolate
administered will
typically be in a range of from about 109 to about 1012 cfu, and more
preferably from
about 101 to about 1 01 1 cfu, respectively. The optimum dosage of a selected
bacterial
isolate can be determined by administering different dosages of the isolate to
different
groups of test mammals, prior to subsequently infecting the animals in each
group with
the corresponding live bacterial pathogen, and determining the dosage level
required to
achieve satisfactory clearance of the pathogen as would be well understood by
the skilled
addressee.
The vaccine itself may be freeze-dried or lyophilised for later reconstitution
utilising a
physiologically acceptable buffer or fluid. The vaccine can also contain one
or more anti-
caking agents, isotonic agents, preservatives such as thimerosal, stabilisers
such as amino
acids and sugar moieties, sweetening agents such sucrose, lactose or
saccharin, pH
modifiers sodium hydroxide, hydrochloric acid, monosodium phosphate and/or
disodium
phosphate, a pharmaceutically acceptable carrier such as physiologically
saline, suitable
buffers, solvents, dispersion media and isotonic preparations. Use of such
ingredients and
media for pharmaceutically active substances and vaccines is well known in the
art.
Except insofar as any conventional media or agent is incompatible with the
bacterial
isolate(s), their use in vaccines of invention is specifically encompassed.
Supplementary
active agents such as one or more cytokines for boosting the immune response,
particularly cytokines characteristic of a Thl response such as IFN- y, IL-12
and TNF-13,
can also be incorporated in the vaccine if desired.
In addition, a vaccine embodied by the invention may also comprise one or more
adjuvants. Suitable adjuvants, pharmaceutically acceptable carriers and
combinations of
ingredients useful in vaccine compositions of the present invention may for
instance be
found in handbooks and texts well known to the skilled addressee such as
"Remington"
CA 02577165 2012-10-25
11
The Science and Practice of Pharmacy (Mack Publishing Co., 1995)",
The oral killed bacterial vaccine may be administered as a dry powder or in
liquid form.
Administration can for example be achieved by aerosol inhalation, as a dosed
liquid, by
instillation, or as a spray. Devices for facilitating for delivery of oral
vaccines are well
known in the art and include metered dose inhalers (MDIs), dry powder inhalers
(DPIs)
and nebulisers including those which use ultrasonic energy or compressed air
or other
propellant to achieve atomisation. Propellants which may be used in MDIs
include for
instance chlorofluorocarbons (CFCs) such as trichlorofluorocarbon (CFC-11) and
dichlorodifluorocarbon (CFC-12) and hydrofluoroalkanes.
In order that the nature of the present invention may be more clearly
understood,
preferred forms thereof will now be described with reference to the following
non-
limiting examples.
EXAMPLE 1: Variation in T-lymphocyte activation following oral
immunisation with killed Ps.aeruginosa oral vaccine
A study was conducted to demonstrate the variability in the capacity of
recipient T cells
to recognise and respond to an unselected isolate of killed bacteria. A cohort
of nine
human subjects with bronchiectasis were given two courses of killed oral
Ps.aeruginosa
(Ps.a) vaccine. Each course comprised administering two tables (each tablet
containing
1011 killed bacteria) per day for three days, with the second course
commencing on day
28. The Ps.aeruginosa isolate used was not selected other than being shown to
be
capable of activating the common mucosal system in an animal model.
Peripheral blood mononuclear cells were used as a source of antigen-primed T
cells and
were isolated from heparinized blood on a Ficoll[PaqueTM density gradient.
After
centrifugation at 200g for 20 mins at 4 C, the cells were collected from the
plasma:ficoll
interface, washed twice with PBS pH 7.4 and then resuspended at 2 x 206
cells/mL in
AIM-V medium containing penicillin (100U/mL), streptomycin (100 lig/mL) and 2-
mercaptoethanol ( 5 x 10-5M). Cells were culture in wells of a 96-well flat-
bottomed
microtiter plate with or without Ps antigen (1 ps/mL) or PHA-P ( 2 ps/mL) in a
total
volume of 200 pL of AIM-V medium. After incubation for 4 days at 37 C in a CO2
incubator, the cultures were pulsed with 0.5 p,Ci per well of 3H-thymidine for
the final 8
hrs before harvesting on a glass fibre filter using a cell harvester. After
drying, the filters
were counted in a scintillation counter. The results were expressed as mean
cpm+ SE.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
12.
Table 1 shows the post oral immunisation mean counts (H3-thymidine uptake
representing antigen-induced proliferation) and the standard errors (SE's) of
the means
(representing the variation in individual responses).
Table 1: T cell Ps.a antigen induced proliferation in humans
DAY PHA Ps. aeruginosa antigen
(lug/m1)
CPM x 00 SE (as % of mean) CPM x 000 SE
(as % of mean)
0 84 13 3 16.5
28 82 12 4.4 65
56 80 12.5 9.5 42
The results shows that a consistent mean stimulation was induced throughout
the study by
the classical non-specific T cell mitogent PHA, with a consistent and small
standard error,
reflecting relatively similar proliferative responses. With Ps.a antigen
stimulation before
oral immunisation, the standard error (SE) is of the same order as that found
with PHA.
However, at days 28 and 56 following oral immunisation, a marked variation in
response
was noted (SE's of 64 and 42). These results show considerable variation in T
cell
responsiveness in vivo reflecting failure to select an isolate to engage the T
cell receptor
of most of the recipients.
As a control, DA rats (four per group) were orally immunised using the same
isolate of
Ps.a. Briefly, rats were given 5 x 108 paraformaldehyde killed Pseudomonas
aeruginosa
in PBS daily for 5 days per week for 2 weeks. Peripheral blood cells were
isolated and
3H-thyrnidine uptake assessed as described above. The results are shown in
Table 2.
Table 2: T cell Ps.a antigen induced proliferation in in-bred rats
H3-thymidine CPM (x 000) SE (x 000) (as % of mean)
Unimmunised 16 19
Immunised (tablet) 35 13
A low SE of 13 was found in the in-bred DA rats (ie reflecting low genetic
variability). It
is concluded that the large SE (ie. reflecting degree of individual variation)
in the human
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
13.
response is mainly due to variation in engagement of the antigen-presenting
cell T-
lymphocyte unit by the unselected vaccine candidate. This variation correlates
with large
differences in the level of protection observed between individuals in the
human study,
reflected by the high level of variation in the reduction in bacterial
colonisation
(measured by numbers of bacteria in sputum) and in sputum purulence (measured
as total
white cell count) as determined at day 31. Specifically, bacteria counts were
reduced in
three subjects (1, 3.0, 1.0 log), remained unchanged in five subjects, and
increased (2
logs) in one subject. The sputum white cell count fell with a mean of 40%
reduction with
a SE of 50%. Hence, the activation of T cells (which are responsible for white
cell
recruitment into the bronchus lumen with subsequent bacterial clearance, eg.
see Dunkley
et al (1994) 'A role for CD4+ T cells from orally immunized rats in enhanced
clearance of
Ps.aeruginosa from the lung. Imniunol 83, 362-369) is also variable,
indicating that the
killed bacterial isolate utilised is not an optimal isolate for use as an oral
killed bacterial
vaccine in the general human population.
EXAMPLE 2: Selection of an optimal isolate for eliciting the release of
cytokines
S. aureus and non-typable H. influenzae isolates obtained from normal human
subjects
were killed by treatment with 2% paraformaldehyde in phosphate buffered saline
(PBS).
After incubation at room temperature for 1 hr, the treated bacteria were
exhaustively
washed in PBS and then tested for viability by culturing on mannitol salt agar
or horse
blood agar plates. The killed bacteria were adjusted to 2 x 109 cfu/mL by
interpolation
from a standard regression curve for Absorbance versus CFU. For use in culture
stimulation, the bacteria from each isolate were adjusted to a final
concentration of 2 x
108 CFU per ml in serum-free AIM-V medium containing penicillin (100U/mL),
streptomycin (100pg/m1) and 2-mercaptoethanol ( 2-ME, 5 x 105M).
For S. aureus isolates, groups of male BALB/c mice (n=5) were given 5 x 109
killed
whole cell bacteria by intragastric administration every 2 days per week for 2
weeks
before challenge with live S. aureus bacteria administered intranasally. The
dose was
determined on the basis similar studies examining variable oral dosage.
Control mice
(n=5) were fed PBS alone. Reduction in colonisation in the nose was determined
at 24-48
hrs after challenge. For the NTHi isolates, groups of male BALB/c mice were
given 5 x
109 killed whole cell bacteria by the intragastric route every 2 days per week
for 2 weeks
followed by intranasal challenge with live NTHi bacteria. Control mice were
again fed
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
14,
PBS alone. Reduction in NTHi colonisation was determined in bronchoalveolar
washings
(BAL) and lung homogenates, at 4 hrs following live challenge.
Human peripheral blood mononuclear cells (PBMNC) were separated from
heparinized
blood by centrifugation on a Ficoll/Paque density gradient. After washing by
centrifugation, PBMNC were cultured in AIM-V medium at 2 x 105 cells per well
with 2
x 106/m1 or 2 x 108 /ml CFU of killed bacteria in a total volume of 300 uL in
wells of a
96-well flat-bottomed microtitre plate. After incubation at 37 C and 5% CO2 in
air for 3
days, the culture supernatants were collected and stored at ¨20 C until assay
for cytokines
by ELISA.
The capacity of individual S. aureus and NTHi isolates to stimulate cytokine
production
was tested using an antigen-presenting cell-T cell culture system. Briefly,
PBMNC ( 2 x
106/m1) containing APC and T cells were stimulated with graded doses of killed
bacteria
in flat-bottomed wells of a 96-well plate for 3 days at 37 C in a CO2
incubator. The
culture supernatants were collected and assayed for IL-12 and IFN-7 by ELISA.
Table 3 shows the results of S. aureus isolates (A2, A3, A8, A15, A28, A19,
A20) tested
for their capacity to stimulate the production of IL-12 and IFN-7. The results
are medians
normalised and expressed as a percentage of control. Variable stimulation of
IL-12 and
IFT\T 7 was observed. Isolates A2, A8, A28 and A19 were greater stimulators of
both IL-
12 and IFN- 7 production than isolates A15, A20 and A3. Compared with the
other
isolates, stimulation with isolate A28 led to a 4-10 fold production of IL-12
and/or IFN-
I'.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
15.
Table 3: Production
of IL-12 and IFN-7 in cultures of peripheral blood
mononuclear cells stimulated with different doses of killed whole cell S.
aureus isolate.
Isolates IL-12 pg/mL IFN- pg/mL
*106 bacteria/1 *108 bacteria/1 106 bacteria/1 108
bacteria/1
A2 147 186.5 2159 891.9
A3 <10 <10 2242 2009
A8 36.5 119 1938 1711
A15 <10 <10 <10 2476
A28 1568 <10 8592 9202
A19 149.3 267.8 800.6 607.4
A20 18.6 26.7 977.9 668.3
* numbers of killed bacteria per ml
When isolates A2, A8 and A28 were tested in cultures using PBMNC from 5 normal
healthy subjects, only isolates A2 and A28 were capable of stimulating
substantial
amounts of IL-12 and IFN- 7 in all subjects (Table 4 and Table 5). These
results indicate
that isolates A2 and A28 are potent stimulators of immunomodulating cytokines
and,
therefore, suitable as candidate immunostimulators, likely to mediate
protective mucosal
immunity in most recipients.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
16.
Table 4:
Production of IL-12 in cultures of human peripheral blood mononuclear
cells from normal healthy subjects stimulated with killed whole cell S. aureus
isolate
Isolates IL-12 ( pg/mL)
Subject 1 Subject 2 Subject 3 Subject 3
Subject 5
*106 *108 106 108 106 108 106 108 106 108
A2
138.6 193.7 11.3 147.5 <10 87.6 nd 264.8 nd 271.8
A8 157
<10 46 10.6 27.6 29.7 nd nd nd nd
A28 112
214.2 <10 137.2 nd 56.9 nd 328.2 nd 454.2
None - <10 - <10 - <10 - <10 - <10
* number of killed bacteria per mL
nd = not determined
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
17.
Table 5: IFN- y production stimulated with killed whole cell S aureus
isolate in
cultures of human peripheral blood mononuclear cells from normal healthy
subjects
Isolates IFN-y ( pg/mL)
Subject 1 Subject 2 Subject 3 Subject 3 Subject 5
*106 *108 106 108 106 108 106 108 106 108
A2 1745 5501 3316 8689 963 8838 nd 12152 nd 6232
A8 3388 4628 7458 7458 6479 8285 nd 11770 Nd nd
A28 724 5368 8547 1032 646 8429 nd 13560 Nd 6544
None - <10 - <10 - <10 - <10 - <10
* numbers of killed bacteria per ml
nd = not determined
All NTHi isolates tested (B3, B4, B6, B10 and B14) were found capable of
stimulating
production of IL-12 and IFN- y in variable amounts irrespective of the doses
of bacteria
used in culture stimulation (Table 6). Isolates B3 and B6 stimulated the
generation of
higher amounts of IL-12 and IFN- 7 compared to the other NTHi isolates. The
results are
medians expressed as a percentage of control.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
18.
Table 6: Production
of IL-12 and IFN- y in cultures of peripheral blood
mononuclear cells (PBMNC) stimulated with killed whole cell non-typable H.
influenzae
isolate
Bacterial IL-12 (pg/mL) IFN- y ( pg/mL)
Isolates
106 bact./m1 108 bactiml 106 bactiml 108
bactiml
*PC *RC PC RC PC RC PC RC
B3 65.5
20 42.8 20.6 1740 316 1723 786
B4 25
13.2 18.2 14.8 956 76 1208 420
B6 40.5
26.9 41.2 34.7 1755 436 2063 1758
B10 18.2
16.2 24.4 21.2 378 53 1002 619
B14 28.6 17.1 18.2 16.8 274 45 1341 713
None 23 19
* PBMNC from normal healthy subjects
EXAMPLE 3: Selection of an optimal isolate of bacteria as an
immunostimulator to reduce mucosal colonisation.
Two mouse mucosal colonisation models were used to determine (1) the reduction
in
colonisation of S aureus in the nasal cavities and (2) the reduction in
colonisation of non-
typable H. influenzae in the lungs following challenge with live bacteria.
In model 1, 8 week old male SPF BALB/c mice ( n=5) were given killed whole
cell
S. aureus bacteria (5 x 109 per mouse) in 300 ul PBS by the intragastric route
every 2
days per week for 2 weeks. Control mice received PBS alone. Paraformaldehyde ¨
killed
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
19.
bacteria from isolates A2, A28, A3, A15, A19 and A20 were tested including an
ATCC
strain as a reference (ATCC 49247), respectively. One day after the final
dose, mice
were challenged with live S. aureus by administering 10 ,1 of 5 x 109
bacteria/ml into
each nostril. At 24-48 hrs after challenge, mice were sacrificed and the nasal
tissues
excised. The tissues were homogenised in PBS and the homogenates collected
then
assayed for bacteria concentration by plating 10-fold serial dilutions of the
homogenates
on mannitol salt agar plates. CFU counts were determined after 24 hr
incubation at 37 C.
Figure 1 shows that mice receiving killed bacteria prepared from isolates A19,
A20, A28,
A2, A3, A8 and A15 had reduced in colonisation compared with controls. The
levels of
protection were dependent on the isolates chosen with effectiveness being A28>
A2>
A8> A3> A15> A20 > A19. Furthermore, the high levels of protection achieved
with
A28, A2 and A8 isolates correlated with their capacity to stimulate high
levels of IL-12
and IFN-y in cultures of human PBMNC ( see Tables 2 and 3).
In model 2, mice (n=5) were given killed whole cell NTHi (5 x 109 per mouse)
in 300 ul
of PBS by the intragastric route every 2 days per week for 2 weeks before
challenge with
10 ul of live bacteria in PBS (5 x 109 per ml) administered by the intranasal
route.
Paraformaldehye-killed bacteria prepared from isolates B3, B14, B16 and B10
were
tested, respectively. At 4 hrs following live challenge, the reduction in
colonisation in
terms of bacterial clearance was determined in broncho-alveolar lavage fluid
(BAL) and
lung homogenates from treated and control mice. As shown in Fig. 2, of the
isolates
tested, B3, B16 and B10 gave the best clearance rate compared to the ATCC
reference
strain and isolate B14. When compared for in vitro stimulation of IL-12 and
IFN- y
production, B3 and B6 isolates gave the best correlation with reduction in
colonisation
(see Table 4).
EXAMPLE 4: Selection of an optimal isolate of bacteria as a candidate
vaccine on the basis of optimal cytokine response in vitro and protection in
vivo
Peripheral blood mononuclear cells (PBMNC) were separated from heparinised
blood
from normal healthy subjects by centrifugation on Ficoll/Paque density
solution. The
cells were collected from the plasma/ficoll interface and washed three times
in PBS by
centrifugation at 200g for 15 mins at 4 C. Before culture, the cells were re-
suspended in
AIM-V serum-free medium at 2 x 106 cells/mL and the viability determined by
trypan-
CA 02577165 2012-10-25
blue exclusion test. One hundred microlitre aliquots of the cell suspension
were added in
duplicates to equal volumes of AIM-V medium containing graded concentrations
of
killed bacteria or medium alone in wells of a flat-bottomed 96-well microtitre
plate. The
cultures were incubated for 3 days at 37 C in an incubator with 5% CO2 in air.
After
5 incubation, the supernatants were collected, pooled and stored at ¨20 C
until assay.
IL-10, IL-12 and IFN- y in culture supernatants were measured by ELISA using
monoclonal antibody pairs with recombinant proteins as standards. Briefly,
wells of a
flat-bottomed microtiter plate were coated with capture antibody overnight at
4 C. After
washing, the wells were blocked with 2% BSA solution in PBS for 60 mins at
room
10 temperature (RT) and followed by washing in PBS/TweenTm. One hundred
microlites of
sample supernatant was added to each well. Following incubation for 90 mins at
RT, the
wells were washed and then 100 ul of biotinylated detector antibody was added.
After
incubation for 90 mins, HRP-conjugated streptavidin solution was added for 30
mins. The
wells were then washed before adding TM:13 substrate solution for 20 mins.
After colour
15 development, the reaction was stopped with sulphuric solution before
reading in an
ELISA plate reader at 450 nm. The amount of cytokine secreted in culture
supernatant
was calculated by interpolation using the standard curve and the results were
expressed as
pg/mL.
Table 7 shows that high levels of IFN- y and IL-12 produced by peripheral
blood
20 mononuclear cells stimulated with S. aureus (isolate A28) or NTHi
(isolate B6) correlated
with high levels of protection in the mouse model of colonisation. In
contrast, there was
no coffelation between isolates (A3 and B10) which stimulated low levels of
cytokines
and high levels of protection. Conversely, no correlation was observed between
isolates
(A19 and B14) which stimulated high levels of cytokines and low levels of
protection.
The results demonstrate that optimal cytolcine response and in vivo protection
are markers
for the selection of an optimal isolate of bacteria as a candidate oral
vaccine or
immunostimulator to enhance mucosal immunity and reduce colonisation in the
airways.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
21.
Table 7. Correlation of in vitro cytokine production with in vivo
bacterial clearance.
Isolate IL-12 (pg/mL) IFN y (pg/mL) Protection (%)
A28 1568 9202 91.3
A3 <10 <10 74.7
A19 267.8 800.6 28
B6 412 1063 100
B10 <10 335 72.2
B14 24 1341 24
EXAMPLE 5: Selection of an optimal isolate based on differential
productio I.
of IL-10 and IL-12 , and the capacity to enhance IFN- y production and
protection
in vivo
Stimulation of PBMNC in culture by different isolates produced different
amounts of IL-
and IL-12 whose ratios correlated with the levels of IFN- y and in vivo
protection. As
shown in Table 8, NTHi isolates (B3 , B6) with a low IL-10/IL-12 ratio were
better
10 stimulators of a Thl response characterised by maximal production of IFN-
y and
decreased colonisation of bacteria in the airways of mice orally immunised
with killed
vaccine isolates compared with controls. Conversely, isolates (B4, B10 and
B14) with
high IL-10/IL-12 ratios correlated with lower production of IFN- y and higher
levels of
colonisation. This was also true for S. aureus isolates where high levels of
IFN- y
correlated with low IL-10/IL-12 ratios and low rates of colonisation (Table
9). Taken
together, the results show that an optimal isolate of bacteria can be selected
as a candidate
vaccine on the basis of low IL-10/IL-12 ratio and high IFN- y and an enhanced
protection
in vivo. Thus, on the basis of these results, an optimal isolate would be
associated with a
cut-off value of IL-10/IL-12 ratio of say <15 and high production of IFN- y
(786 pg/ml
for NTHi and > 500 pg/ml for S. aureus) for all healthy subjects tested
(minimum of 3
subjects).
CA 02577165 2007-02-15
WO 2006/017895
PCT/AU2005/001230
22.
Table 8. Selection of non-typable H influenzae isolates based on IL-
10/IL-12 ratio
and IFN- y production and protection in vivo
NTHi Subject 1 Subject 2 Subject 3
Bacteria
Colonisation*
Isolate IL-10/ IFN- y IL-10/ IFN- y IL-10/ IFN- y
(pg/ml)
IL-12 IL-12 (pg/ml) IL-12 (pg/ml) % of Control
Ratio Ratio Ratio
B3 10.9 1010 2.0 1740 1.25 786 37
B6 7 1645 2.5 2063 0.41 1758 55
B4 23.8 532 26.4 956 6.7 76 100
B10 720 236 16.8 690 80 53 100
B14 749 45 22 897 29.8 45 76
Control 51 0 10 23 1.24 19 100
* Colonisation rate in the airways of mice ( n=10) orally immunised with
killed
whole cell bacteria isolate or mice given PBS only (Control)
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
23.
Table 9. Selection of S. aureus isolates based on IL-10/IL-12 ratio and
IFN- y
production and protection in vivo
Subject 1 Subject 2 Subject 3 Bacteria
S. aureus
Colonisation*
Isolate IL-10/ IFN- y IL-10/ IFN- y IL-10/ IFN-
(log/n11) (pg/ml) (Pg./nil)
IL-12 IL-12 IL-12
% of Control
Ratio Ratio Ratio
A2 0.99 5501 2.5 8639 5.9 8839 9.7
A8 3.75 4623 13.2 7620 10.3 8250 26.2
A28 1.6 5638 4.9 8547 14.3 8429 8.7
A19 24 197 3.9 607 20.9 714 72
A20 18 222 38.8 668 125.3 1075 62.5
Control 2 9.8 2 198 2.3 230 100
*Colonisation rate in the noses of mice ( n=10) orally immunised with killed
whole cell bacteria isolate or mice given PBS only (Control)
EXAMPLE 6: Stimulation of peripheral blood mononuclear cells by non-
typable H influenzae isolate NTHi 164
Whole killed NTHi 164 was cultured with PBMNC from normal healthy controls and
IFN-y production assessed. The results are shown in Table 10.
CA 02577165 2007-02-15
WO 2006/017895 PCT/AU2005/001230
24.
Table 10: Stimulation of IFN-7 production in PBMNC stimulated with whole
killed
NTHi 164 isolate
Whole killed Subject
NTHi 164
MD PH PC RC
IFN-7 (pg/ml)
106 bacteria/mL 207 257 491 72
108 bacteria/mL 1738 1193 4533 514
Compared to Table 6 in Example 2, NTHi 164 expressed comparable levels of IFN7
for
RC and higher level for PC than elicited by NTHi isolates B3 or B6. A
particulate
fraction of the NTHi isolate was also prepared and the capacity of the
fraction to
stimulate IFN-7 production assessed. The results are shown in Table 11.
Briefly, NTHi
164 was revived from -80 C storage onto chocolate agar plates then
subcultured on
chocolate agar. The bacteria were harvested, pelleted, washed and resuspended
to
1010/m1 in PBS. The suspension was sonicated at an amplitude of 61.tusing 10
cycles of
30 seconds on and 60 seconds off. The suspension was centrifuged at 7000g and
the
supernatant collected, sterile filtered, and protein content determined by
Pierce BCA
protein assay. Aliquots were stored frozen at ¨ 20 C until use.
Table 11: Stimulation of IFN-7 production in PBMNC particulate antigen of
whole
killed NTHi 164 isolate
NTHi 164 Subject
antigen
1 2 3 4 5 6 7
IFN-7 (pg/ml)
111g/mL 130 287 24 111 156 86 35
10 g/mL 368 = 128 101 169 356 565 334
CA 02577165 2012-10-25
Tables 10 and 11 show that both whole killed NTHi 164 and the particulate
antigen
extract of the isolate stimulates peripheral blood mononuclear cells to
produce IFN-y.
The production of IFN-y is IL-12 dependent.
It will be appreciated by persons skilled in the art that numerous variations
and/or
5 modifications may be made to the invention as shown in the specific
embodiments.
The present embodiments are, therefore, to be considered in all respects as
illustrative and not restrictive. The scope of the claims should not be
limited by the
preferred embodiments set forth in the examples, but should be given the
broadest
interpretation consistent with the description as a whole.
CA 02577165 2007-02-15
WO 2006/017895
PCT/AU2005/001230
26.
REFERENCES
1. Dunldey et al, Immunol. (1994) 83, Pp. 362-369
2. Remington. "The Science and Practice of Pharmacy." (Mack Publishing Co.,
1995)
